Personal profile
Education
- Ph.D., Institute of Clinical Medicine, National Cheng Kung University (NCKU)
- M.S., Institute of Clinical Medicine, National Cheng Kung University (NCKU)
- M.D., School of Medicine, Kaohsiung Medical University
Experience
- Associate Investigator & Attending Physician, National Institute of Cancer Research, NHRI
- Assistant Professor, Department of Oncology, College of Medicine, NCKU
- Attending Physician, Division of Hematology & Oncology, Department of Internal Medicine, NCKU Hospital
- Assistant Investigator & Attending Physician, National Institute of Cancer Research, NHRI
- Postdoctoral Fellow, Department of Oncology, Johns Hopkins University School of Medicine
- Attending Physician, National Institute of Cancer Research, NHRI
- Resident, Department of Internal Medicine, NCKU Hospital
- Attending Physician, Division of Hematology & Oncology, Department of Oncology, NCKU Hospital
- Associate Professor, Department of Oncology, College of Medicine, NCKU
- Associate Professor, Department & Institute of Pharmacology, College of Medicine, NCKU
- Jointly Appointed Physician & Division Chief, Cell Therapy Center, NCKU Hospital / NHRI
Research Interests
- Cancer Treatment (Urological Cancer, etc.)
- Oncology Research
- Anti-cancer Drug Development
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Revealing the Roles of the SH3GLB1-Hydrogen Peroxide Axis in Glioblastoma Multiforme Cells
Hsueh, W. T., Chang, K. Y., Tsai, C. C., Chen, K. T., Tsai, K. J., Hong, Z. X., Liu, C. C., Chu, J. M., Qiu, L. Y., Lan, Y. Y. & Chien, C. H., 2026, In: Oncology Research. 34, 2, 15.Research output: Contribution to journal › Article › peer-review
Open Access -
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors
Chiang, N. J., Bai, L. Y., Ho, I. W., Hsu, C. H., Liang, Y. H., Chiu, C. F., Lin, C. C., Chang, K. Y., Chen, S. H., Tsai, H. J., Lin, Y. P., Chen, L. T. & Lin, C. C., 2025 Jun, In: Investigational New Drugs. 43, 3, p. 709-718 10 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Citations (Scopus) -
Cathepsin S regulates antitumor immunity through autophagic degradation of PD-L1 in colorectal cancer cells
Taheri Baghmisheh, S., Chen, C. H., Yeh, Y. M., Lin, P. C., Chen, P.-C., Chan, R. H., Kang, J.-W., Lee, C. T., Tsai, H. J., Fang, Y. C., Cheung, C. H. A., Chang, K. Y., Chang, J. Y. & Chen, S. H., 2025 Sept, In: Cancer Immunology, Immunotherapy. 74, 9, 287.Research output: Contribution to journal › Article › peer-review
Open Access3 Link opens in a new tab Citations (Scopus) -
Contribution of Prostaglandin E2-Induced Neuronal Excitation to Drug Resistance in Glioblastoma Countered by a Novel Blood–Brain Barrier Crossing Celecoxib Derivative
Shen, C. J., Chen, H. C., Lin, C. L., Thakur, A., Onuku, R., Chen, I. C., Li, H. Y., Chang, K. Y., Chuang, J. Y., Yang, W. B., Lin, H. Y., Shen, Y. R., Liou, J. P., Chang, W. C. & Hsu, T. I., 2025 Oct 13, In: Advanced Science. 12, 38, e06336.Research output: Contribution to journal › Article › peer-review
Open Access5 Link opens in a new tab Citations (Scopus) -
Correction: SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma (Journal of Experimental & Clinical Cancer Research, (2022), 41, 1, (220), 10.1186/s13046-022-02429-8)
Chien, C. H., Yang, W. B., Chuang, J. Y., Lee, J. S., Liao, W. A., Huang, C. Y., Chen, P. Y., Wu, A. C., Yang, S. T., Lai, C. C., Chi, P. I., Chu, J. M., Cheng, S. M., Liu, C. C., Hwang, D. Y., Chen, S. H. & Chang, K. Y., 2025 Dec, In: Journal of Experimental and Clinical Cancer Research. 44, 1, 179.Research output: Contribution to journal › Comment/debate › peer-review
Open Access